CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

RVTY's strong product portfolio raises optimism about the stock.

QDEL's strong product portfolio raises optimism about the stock.

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

STE's strong prospects in the healthcare business arm bode well for investors.

Rising healthcare spending and aging population aid Ventas' senior housing operating portfolio. However, tenant concentration and high interest rates...

Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.

Investors remain optimistic about Patterson Companies on the back of its broad product line.

Investors remain optimistic about Patterson Companies on the back of its broad product line.

Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.